ORIC Pharmaceuticals Inc.

Overcoming Resistance In Cancer

Add To Watchlist
General Information
Company Name
ORIC Pharmaceuticals Inc.
Founded Year
2014
Location (Offices)
South San Francisco, United States +2
Founders / Decision Makers
Pratik Multani - Chief Medical Officer Edna Chow Maneval - Senior Vice President, Clinical Development Jacob Chacko - Chief Executive Officer Amanda Albert - Senior Director of Program Management Lori Friedman - Chief Scientific Officer Charles Sawyers - Founder Dominic Piscitelli - Chief Financial Officer
Number of Employees
119
Industries
Biopharma, Biotechnology, Health Care +2
Funding Stage
Post Ipo Equity
Social Media

ORIC Pharmaceuticals Inc. - Company Profile

ORIC Pharmaceuticals Inc. is a clinical stage biopharmaceutical company with the slogan "Overcoming Resistance In Cancer". The company is dedicated to improving patients’ lives by developing innovative solutions for cancer treatment. Their clinical stage product candidates include ORIC-114, a brain penetrant inhibitor targeting EGFR and HER2 with high potency against exon 20 insertion mutations, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for multiple myeloma. Additionally, ORIC is working on developing precision medicines targeting other hallmark cancer resistance mechanisms. Established in 2014, ORIC Pharmaceuticals is headquartered in the United States with offices in South San Francisco and San Diego, California. The company recently secured a $125.00M Post-IPO Equity investment on 30 January 2024. For more information, please visit their website at www.oricpharma.com and follow them on X or LinkedIn.

Taxonomy: cancer research, precision medicine, clinical-stage biopharmaceutical company, oncology, immunotherapy, drug development, cancer resistance mechanisms, glucocorticoid receptor antagonist, small molecule inhibitors, targeted therapy, clinical trials, biopharmaceutical innovation

Funding Rounds & Investors of ORIC Pharmaceuticals Inc. (7)

View All
Funding Stage Amount No. Investors Investors Date
Post-IPO Equity $125.00M - 30 Jan 2024
Post-IPO Equity $85.00M 6
Boxer Capital, investor in ORIC Pharmaceuticals Inc.'s Post-IPO Equity round EcoR1 Capital, investor in ORIC Pharmaceuticals Inc.'s Post-IPO Equity round Nextech Invest, investor in ORIC Pharmaceuticals Inc.'s Post-IPO Equity round Montauk Ventures, investor in ORIC Pharmaceuticals Inc.'s Post-IPO Equity round Venrock Healthcare Capital Partners, investor in ORIC Pharmaceuticals Inc.'s Post-IPO Equity round Frazier Life Sciences, investor in ORIC Pharmaceuticals Inc.'s Post-IPO Equity round
26 Jun 2023
Post-IPO Equity $25.00M 1 Pfizer 21 Dec 2022
Series D $55.00M 10
OrbiMed, investor in ORIC Pharmaceuticals Inc.'s Series D round The Column Group, investor in ORIC Pharmaceuticals Inc.'s Series D round Invus, investor in ORIC Pharmaceuticals Inc.'s Series D round Foresite Capital, investor in ORIC Pharmaceuticals Inc.'s Series D round Hartford HealthCare Endowment, investor in ORIC Pharmaceuticals Inc.'s Series D round Irving Investors, investor in ORIC Pharmaceuticals Inc.'s Series D round Taiho Ventures, investor in ORIC Pharmaceuticals Inc.'s Series D round Topspin Partners, investor in ORIC Pharmaceuticals Inc.'s Series D round
Memorial Sloan - Kettering Cancer Center, Kravis Investment Partners 		09 Aug 2019
Series C $50.00M 10
OrbiMed, investor in ORIC Pharmaceuticals Inc.'s Series C round The Column Group, investor in ORIC Pharmaceuticals Inc.'s Series C round Fidelity, investor in ORIC Pharmaceuticals Inc.'s Series C round Foresite Capital, investor in ORIC Pharmaceuticals Inc.'s Series C round NS Investment, investor in ORIC Pharmaceuticals Inc.'s Series C round Taiho Ventures, investor in ORIC Pharmaceuticals Inc.'s Series C round Trinitas Capital, investor in ORIC Pharmaceuticals Inc.'s Series C round
Topspin Fund, Memorial Sloan - Kettering Cancer Center +1 		21 Feb 2018

View All 7 Funding Rounds

Latest News of ORIC Pharmaceuticals Inc.

View All

No recent news or press coverage available for ORIC Pharmaceuticals Inc..

Similar Companies to ORIC Pharmaceuticals Inc.

View All
Cascadian Therapeutics, Inc. - Similar company to ORIC Pharmaceuticals Inc.
Cascadian Therapeutics, Inc.
Treadwell Therapeutics, Inc. - Similar company to ORIC Pharmaceuticals Inc.
Treadwell Therapeutics, Inc. The Path to Better
MEI Pharma - Similar company to ORIC Pharmaceuticals Inc.
MEI Pharma Committed to the development of novel, best-in-class, cancer therapies intended to provide improved outcomes to patients
Rexahn Pharmaceuticals - Similar company to ORIC Pharmaceuticals Inc.
Rexahn Pharmaceuticals TARGETING DIFFICULT TO TREAT CANCERS
Sutro Biopharma, Inc. - Similar company to ORIC Pharmaceuticals Inc.
Sutro Biopharma, Inc. Changing the future of Oncology
Circle Decoration Circle Decoration

Want to dive deeper into ORIC Pharmaceuticals Inc.? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now